Brief: Clarity Advances To Cohort 3 Of CL04 Trial Of Sartate In Paediatric Neuroblastoma
23/08/2022 14:07
Aug 23 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* CLARITY ADVANCES TO COHORT 3 OF CL04 TRIAL OF SARTATE™ IN
PAEDIATRIC NEUROBLASTOMA
Source text for Eikon: ID:nPn2gHpbPa
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial